Pyrotinib
Mismatch Repair Deficiency
Floor Backes, MDSmall moleculeEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
20 Active assets in the Mismatch Repair Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab 7 Hills Pharma, LLC | Phase 2 | B |
Pembrolizumab Jennifer Leddon | Phase 2 | B |
Cyclophosphamide Jennifer Leddon | Phase 2 | B |
Danvatirsen M.D. Anderson Cancer Center | Phase 2 | CCC |
Durvalumab ImmunityBio, Inc. | Phase 2 | CCC |
View all 25 →
Same molecule, other indications
Pyrotinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →